A study testing whether 177Lu-DTPA-omburtamab is safe for children and teens with brain cancer
Original title: A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing if a treatment called 177Lu-DTPA-omburtamab is safe for young people whose cancer is in the brain or spinal cord.
Who this trial is for. This trial is for children and teens with medulloblastoma, a type of brain tumor, that came back or did not respond to treatment. It is also for young people with another kind of cancer that has spread to the central nervous system, which means the brain and spinal cord. The trial is testing whether a treatment called 177Lu-DTPA-omburtamab is safe for them.
Where it stands. This trial is looking at how safe the treatment is. That answer is not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: Safety is the first thing doctors need to learn about a new treatment. If your child fits the group this trial is for, you can ask your care team about it. They can tell you if it makes sense to look into.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Joining one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.